ASCO Names CAR T-Cell Therapy as Cancer Advance of the Year – OncLive
OncLive |
ASCO Names CAR T-Cell Therapy as Cancer Advance of the Year
OncLive The FDA approved a pair of CAR T-cell therapies in 2017: tisagenlecleucel (Kymriah) for the treatment of children and young adults aged up to 25 with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) and axicabtagene ciloleucel … CAR T-cell therapy named ASCO's 'Advance of the Year' |
